Open AccessEffect of Medicine on Interleukin-6 Inhibitors and their Forms Against COVID-19
Author(s) -
Kevser Kuşat,
Sinan Akgöl
Publication year - 2021
Publication title -
biointerface research in applied chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.216
H-Index - 11
ISSN - 2069-5837
DOI - 10.33263/briac121.756767
Subject(s) - covid-19 , medicine , coronavirus , pharmacology , drug , clinical trial , disease , nanomedicine , virology , infectious disease (medical specialty) , nanotechnology , outbreak , materials science , nanoparticle
Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), previously known as the 2019 novel coronavirus (2019-nCoV). The first cases were seen in December 2019 in Wuhan. To date, there is no specific treatment for COVID-19 disease. Recent clinical trials suggest that interleukin-6 (IL-6) inhibitors and their derivates could play a role as a therapeutic agent against COVID-19. It is prominent to assess potential therapeutic effects of drugs that are clinically approved for other indications. In addition, IL-6 inhibitors have been used in nanomedicine. This review focuses on the development of nanosystems for the therapy of COVID-19. IL-6 inhibitors and signal pathway inhibitors attached to biocompatible nanomaterials may provide a useful route for the treatment of COVID-19. This review would also help scientists who make potential drug research via attachment of interleukin-6 inhibitors and their derived forms to biocompatible nanomaterials for treatment of COVID-19.